Büşra Kaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Büşra Kaya has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Bahri Ülküseven
Department of Chemistry, Faculty of Engineering Istanbul University‐Cerrahpasa Istanbul Turkey
11 shared publications Onur Şahin
Department of Occupational Health & Safety, Faculty of Health Sciences, Sinop University, Sinop, Turkey
5 shared publicationsBahri Ülküseven
Department of Chemistry, Faculty of Engineering, Istanbul University-Cerrahpasa, Istanbul, Turkey
4 shared publicationsBelma Aslim
Faculty of Science, Department of Biology, Gazi University, 06500 Ankara, Turkey
3 shared publications- Onur Şahin
Sinop University, Faculty of Health Sciences, Department of Occupational Health and Safety, Sinop, Türkiye
3 shared publications - Atıf Koca
Faculty of Engineering, Chemical Engineering Department, Marmara University, İstanbul, Türkiye
2 shared publications
Latest Publications
- Open Access
- 29 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11581
Lysosome as a Chemical Reactor
The lysosome is no longer viewed as a simple degradative “trash can” of the cell. The lysosome is not only degradative; its acidic, redox-active lumen also serves as a chemical “microreactor” that can modulate anticancer drug disposition and activation. This review examines how the distinctive chemical features of the lysosome, including its acidic pH (~4.5–5), strong redox gradients, limited thiol-reducing capacity, generation of reactive oxygen (ROS), diverse acid hydrolases, and reservoirs of metal ions, converge to influence the fate and activity of anticancer drugs. The acidic lumen promotes sequestration of weak-base drugs, which can reduce efficacy by trapping agents within a protective “safe house,” yet can also be harnessed for pH-responsive drug release. Lysosomal redox chemistry, driven by intralysosomal iron and copper, catalyzes Fenton-type ROS generation that contributes to oxidative damage and ferroptosis. The lysosome’s broad enzyme repertoire enables selective prodrug activation, such as through protease-cleavable linkers in antibody–drug conjugates, while its membrane transporters, particularly P-glycoprotein (Pgp), can sequester chemotherapies and promote multidrug resistance. Emerging therapeutic strategies exploit these processes by designing lysosomotropic drug conjugates, pH- and redox-sensitive delivery systems, and combinations that trigger lysosomal membrane permeabilization (LMP) to release trapped drugs. Acridine–thiosemicarbazone hybrids exemplify this approach by combining lysosomal accumulation with metal-based redox activity to overcome Pgp-mediated resistance. Advances in chemical biology, including fluorescent probes for pH, redox state, metals, and enzymes, are providing new insights into lysosomal function. Reframing the lysosome as a chemical reactor rather than a passive recycling compartment opens new opportunities to manipulate subcellular pharmacokinetics, improve drug targeting, and overcome therapeutic resistance in cancer. Overall, this review translates the chemical principles of the lysosome into design rules for next-generation, more selective anticancer strategies.
- 29 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11581
Open AccessLysosome as a Chemical Reactor
The lysosome is no longer viewed as a simple degradative “trash can” of the cell. The lysosome is not only degradative; its acidic, redox-active lumen also serves as a chemical “microreactor” that can modulate anticancer drug disposition and activation. This review examines how the distinctive chemical features of the lysosome, including its acidic pH (~4.5–5), strong redox gradients, limited thiol-reducing capacity, generation of reactive oxygen (ROS), diverse acid hydrolases, and reservoirs of metal ions, converge to influence the fate and activity of anticancer drugs. The acidic lumen promotes sequestration of weak-base drugs, which can reduce efficacy by trapping agents within a protective “safe house,” yet can also be harnessed for pH-responsive drug release. Lysosomal redox chemistry, driven by intralysosomal iron and copper, catalyzes Fenton-type ROS generation that contributes to oxidative damage and ferroptosis. The lysosome’s broad enzyme repertoire enables selective prodrug activation, such as through protease-cleavable linkers in antibody–drug conjugates, while its membrane transporters, particularly P-glycoprotein (Pgp), can sequester chemotherapies and promote multidrug resistance. Emerging therapeutic strategies exploit these processes by designing lysosomotropic drug conjugates, pH- and redox-sensitive delivery systems, and combinations that trigger lysosomal membrane permeabilization (LMP) to release trapped drugs. Acridine–thiosemicarbazone hybrids exemplify this approach by combining lysosomal accumulation with metal-based redox activity to overcome Pgp-mediated resistance. Advances in chemical biology, including fluorescent probes for pH, redox state, metals, and enzymes, are providing new insights into lysosomal function. Reframing the lysosome as a chemical reactor rather than a passive recycling compartment opens new opportunities to manipulate subcellular pharmacokinetics, improve drug targeting, and overcome therapeutic resistance in cancer. Overall, this review translates the chemical principles of the lysosome into design rules for next-generation, more selective anticancer strategies.
- Open Access
- 14 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (22) , 11008
Transmetalation in Cancer Pharmacology
Transmetalation, the exchange of metal ions between coordination complexes and biomolecules, has emerged as a powerful design lever in cancer metallopharmacology. Using thiosemicarbazones (TSCs) as a unifying case study, we show how redox-inert carrier states such as zinc(II) or gallium(III) can convert in situ into redox-active copper(II) or iron(III/II) complexes within acidic, metal-rich lysosomes. This conditional activation localizes reactive oxygen species (ROS) generation and iron deprivation to tumor cells. We critically compare redox-active and redox-inert states, delineating how steric and electronic tuning, backbone rigidity, and sulfur-to-selenium substitution govern exchange hierarchies and kinetics. We further map downstream consequences for metal trafficking, lysosomal membrane permeabilization, apoptosis, and ferroptosis. Beyond TSCs, iron(III)-targeted transmetalation from titanium(IV)-chelator “chemical transferrin mimetics” illustrates a generalizable Trojan horse paradigm. We conclude with translational lessons, including mitigation of hemoprotein oxidation via steric shielding, stealth zinc(II) prodrugs, and dual-chelator architectures and outline biomarker, formulation, and imaging strategies that de-risk clinical development. Collectively, these insights establish transmetalation as a central therapeutic principle. We also highlight open challenges such as quantifying in-cell exchange kinetics, predicting speciation under non-equilibrium conditions, and rationally combining these agents with existing therapies.
- 14 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (22) , 11008
Open AccessTransmetalation in Cancer Pharmacology
Transmetalation, the exchange of metal ions between coordination complexes and biomolecules, has emerged as a powerful design lever in cancer metallopharmacology. Using thiosemicarbazones (TSCs) as a unifying case study, we show how redox-inert carrier states such as zinc(II) or gallium(III) can convert in situ into redox-active copper(II) or iron(III/II) complexes within acidic, metal-rich lysosomes. This conditional activation localizes reactive oxygen species (ROS) generation and iron deprivation to tumor cells. We critically compare redox-active and redox-inert states, delineating how steric and electronic tuning, backbone rigidity, and sulfur-to-selenium substitution govern exchange hierarchies and kinetics. We further map downstream consequences for metal trafficking, lysosomal membrane permeabilization, apoptosis, and ferroptosis. Beyond TSCs, iron(III)-targeted transmetalation from titanium(IV)-chelator “chemical transferrin mimetics” illustrates a generalizable Trojan horse paradigm. We conclude with translational lessons, including mitigation of hemoprotein oxidation via steric shielding, stealth zinc(II) prodrugs, and dual-chelator architectures and outline biomarker, formulation, and imaging strategies that de-risk clinical development. Collectively, these insights establish transmetalation as a central therapeutic principle. We also highlight open challenges such as quantifying in-cell exchange kinetics, predicting speciation under non-equilibrium conditions, and rationally combining these agents with existing therapies.
- 9 June 2023
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 47 (30) , 14225-14241
In vitrobiological andin silicoscreening of novel iron(iii) complexes for DNA-targeted antitumor drug component
Two novel thiosemicarbazone-based iron(III) complexes (Fe1 and Fe2) were synthesized and identified by analytical and spectroscopic methods. Their antiproliferative activity was investigated using the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) test against HT-29, HeLa, and L929 cell lines. The interaction between the complexes and calf thymus DNA were determined using electronic spectra and fluorescence spectra analysis. Gel electrophoresis was used to examine DNA cleavage and human topoisomerase-IIα inhibitory action. The complexes were screened for xanthine oxidase (XO) inhibitory activity and their antioxidant activities were determined by 2,2-diphenyl-1-picrylhydrazyl (DPPH) and phosphomolybdenum methods. In silico screening was performed to evince some pharmacological characteristics such as drug-likeness, bioactivity score and probable activity spectra of compounds (PASS) analysis using Molinspiration and PASS software. The iron(III) complexes promoted the cleavage of DNA from the supercoiled form (Form I) to the nicked circular form (Form II), but did not create Form III, indicating single-stranded DNA cleavage. MTT results showed that Fe2 has more effective antiproliferative activity on HT-29 cells, Fe1 has more effective antiproliferative activity on HeLa cells, and the complexes generally moderately affect normal fibroblast L929 cells. The antiproliferation levels were consistent with the DNA interaction results. Both complexes had antioxidant activity and inhibited XO better than the standard drug allopurinol. In silico studies have shown that the iron(III) complexes can have drug-like characteristics associated with remarkable pharmacokinetic properties that make sense of the experimental data regarding DNA-targeting, antioxidant, topoisomerase-IIα and XO inhibitory abilities.
- 9 June 2023
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 47 (30) , 14225-14241
In vitrobiological andin silicoscreening of novel iron(iii) complexes for DNA-targeted antitumor drug component
Two novel thiosemicarbazone-based iron(III) complexes (Fe1 and Fe2) were synthesized and identified by analytical and spectroscopic methods. Their antiproliferative activity was investigated using the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) test against HT-29, HeLa, and L929 cell lines. The interaction between the complexes and calf thymus DNA were determined using electronic spectra and fluorescence spectra analysis. Gel electrophoresis was used to examine DNA cleavage and human topoisomerase-IIα inhibitory action. The complexes were screened for xanthine oxidase (XO) inhibitory activity and their antioxidant activities were determined by 2,2-diphenyl-1-picrylhydrazyl (DPPH) and phosphomolybdenum methods. In silico screening was performed to evince some pharmacological characteristics such as drug-likeness, bioactivity score and probable activity spectra of compounds (PASS) analysis using Molinspiration and PASS software. The iron(III) complexes promoted the cleavage of DNA from the supercoiled form (Form I) to the nicked circular form (Form II), but did not create Form III, indicating single-stranded DNA cleavage. MTT results showed that Fe2 has more effective antiproliferative activity on HT-29 cells, Fe1 has more effective antiproliferative activity on HeLa cells, and the complexes generally moderately affect normal fibroblast L929 cells. The antiproliferation levels were consistent with the DNA interaction results. Both complexes had antioxidant activity and inhibited XO better than the standard drug allopurinol. In silico studies have shown that the iron(III) complexes can have drug-like characteristics associated with remarkable pharmacokinetic properties that make sense of the experimental data regarding DNA-targeting, antioxidant, topoisomerase-IIα and XO inhibitory abilities.
- 1 February 2023
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 37 (4)
Synthesis, SARS‐CoV‐2 3CL main protease inhibitor, anti‐inflammatory, and wound‐healing effects of a zinc(II)‐thiosemicarbazone complex
A new zinc(II) complex with tetradentate thiosemicarbazone (2) was synthesized to investigate the effectiveness against SARS‐CoV‐2 virus and its anti‐inflammatory effects on BEAS‐2B human bronchial epithelial cells. Structural confirmation was performed by IR, 1H and 13C NMR, and ESI‐MS spectroscopies. The results showed that the complex 2 molecule inhibits 3CL main protease enzyme. It was found that complex 2 had a proliferative effect at low doses. TNF‐α stimulation significantly increased IL8 gene expression 3.42 ± 0.107 fold in BEAS‐2B cells (p = 0.037). However, it was found that all concentrations of complex 2 highly suppressed IL8 gene expression in the control group and TNF‐α‐stimulated BEAS‐2B cells (p = 0.009). The healing rate of complex 2 was higher than the control and BEAS‐2B cells induced by TNF‐α at the 24 and 48 h after wound formation. It is known that the biological efficiency of metal‐thiosemicarbazone complexes was adjusted depending on substituent and metal. In this context, complex 2 may be considered as a precursor molecule in the investigation of the antiviral and anti‐inflammatory effects of those formed with the element zinc. Investigation of the selectivity of the inhibitory effect of complex 2 on the 3CL main protease is important for a more detailed understanding of its antiviral effect potential. Although the 3CL main protease enzyme was concentrated in antiviral effective molecule screening studies against SARS‐CoV‐2 virus, the fact that complex 2 also has anti‐inflammatory and wound‐healing effects is a distinguishing feature from other inhibitory effective molecules.
- 1 February 2023
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 37 (4)
Synthesis, SARS‐CoV‐2 3CL main protease inhibitor, anti‐inflammatory, and wound‐healing effects of a zinc(II)‐thiosemicarbazone complex
A new zinc(II) complex with tetradentate thiosemicarbazone (2) was synthesized to investigate the effectiveness against SARS‐CoV‐2 virus and its anti‐inflammatory effects on BEAS‐2B human bronchial epithelial cells. Structural confirmation was performed by IR, 1H and 13C NMR, and ESI‐MS spectroscopies. The results showed that the complex 2 molecule inhibits 3CL main protease enzyme. It was found that complex 2 had a proliferative effect at low doses. TNF‐α stimulation significantly increased IL8 gene expression 3.42 ± 0.107 fold in BEAS‐2B cells (p = 0.037). However, it was found that all concentrations of complex 2 highly suppressed IL8 gene expression in the control group and TNF‐α‐stimulated BEAS‐2B cells (p = 0.009). The healing rate of complex 2 was higher than the control and BEAS‐2B cells induced by TNF‐α at the 24 and 48 h after wound formation. It is known that the biological efficiency of metal‐thiosemicarbazone complexes was adjusted depending on substituent and metal. In this context, complex 2 may be considered as a precursor molecule in the investigation of the antiviral and anti‐inflammatory effects of those formed with the element zinc. Investigation of the selectivity of the inhibitory effect of complex 2 on the 3CL main protease is important for a more detailed understanding of its antiviral effect potential. Although the 3CL main protease enzyme was concentrated in antiviral effective molecule screening studies against SARS‐CoV‐2 virus, the fact that complex 2 also has anti‐inflammatory and wound‐healing effects is a distinguishing feature from other inhibitory effective molecules.
- Open Access
- 31 August 2022
- Published by The Turkish Chemical Society in Journal of the Turkish Chemical Society Section A: Chemistry
- Vol. 9 (3) , 867-878
An Iron(III)-S-methylthiosemicarbazone Complex: Synthesis, Spectral Characterization, and Antioxidant Potency Measured by CUPRAC and DPPH Methods
An iron(III) complex, [Fe(L1)Cl].H2O, was synthesized by template condensation reaction of 1,1,1-Trifluoroacetylacetone-S-methylthiosemicarbazone hydrogen iodide (L) and 2,3-dihydroxybenzaldehyde in the presence of iron(III) ions. The complex was characterized by IR, ESI MS and X-ray diffraction techniques. Free radical scavenging (FRS) ability and antioxidant capacity of the S-methylthiosemicarbazone and the iron(III) complex were evaluated through DPPH and CUPRAC methods, respectively. The complex exerted better than the S-methylthiosemicarbazone in both TEAC and FRS% values. In addition, iron(III) complex was found to be 3.1 times more antioxidant than the reference ascorbic acid according to the CUPRAC method.
- 31 August 2022
- Published by The Turkish Chemical Society in Journal of the Turkish Chemical Society Section A: Chemistry
- Vol. 9 (3) , 867-878
Open AccessAn Iron(III)-S-methylthiosemicarbazone Complex: Synthesis, Spectral Characterization, and Antioxidant Potency Measured by CUPRAC and DPPH Methods
An iron(III) complex, [Fe(L1)Cl].H2O, was synthesized by template condensation reaction of 1,1,1-Trifluoroacetylacetone-S-methylthiosemicarbazone hydrogen iodide (L) and 2,3-dihydroxybenzaldehyde in the presence of iron(III) ions. The complex was characterized by IR, ESI MS and X-ray diffraction techniques. Free radical scavenging (FRS) ability and antioxidant capacity of the S-methylthiosemicarbazone and the iron(III) complex were evaluated through DPPH and CUPRAC methods, respectively. The complex exerted better than the S-methylthiosemicarbazone in both TEAC and FRS% values. In addition, iron(III) complex was found to be 3.1 times more antioxidant than the reference ascorbic acid according to the CUPRAC method.
- 1 February 2022
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1250, 131783
Four and six-coordinated cobalt complexes based on thiosemicarbazone. Formation, experimental and theoretical characterization
- 1 February 2022
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1250, 131783
Four and six-coordinated cobalt complexes based on thiosemicarbazone. Formation, experimental and theoretical characterization
- 1 October 2021
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1242, 130674
S-alkylated thiosemicarbazone derivatives: Synthesis, crystal structure determination, antimicrobial activity evaluation and molecular docking studies
- 1 October 2021
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1242, 130674
S-alkylated thiosemicarbazone derivatives: Synthesis, crystal structure determination, antimicrobial activity evaluation and molecular docking studies
- 15 July 2020
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 34 (11)
Cobalt(II)/(III) complexes bearing a tetradentate thiosemicarbazone: Synthesis, experimental and theoretical characterization, and electrochemical and antioxidant properties
New cobalt complexes, Co1 and Co2, were synthesized starting from acetylacetone‐S‐methylthiosemicarbazone. The square planar cobalt(II) and octahedral cobalt(III) complexes were characterized by FT‐IR, UV–visible, 1H NMR, and X‐ray diffraction spectroscopies and mass spectrometry. Frontier orbitals of the complexes were theoretically obtained to better understand the complex structures and intermolecular interactions. The electrochemical behaviors of Co1 and Co2 were investigated and the results were evaluated by comparing with each other and with similar published compounds to determine their possible usage in various electrochemical technologies, such as energy storage devices, electrocatalysts, and electrosensors. Metal‐based oxidation at around 0 V and metal‐based reduction at around −1.0 V indicated that these complexes are valuable for the proposed applications. By determining the trolox equivalent antioxidant capacity and the radical scavenging activity of the cobalt complexes, the compatibility between the antioxidant qualification, redox, and theoretical calculation results was discussed.
- 15 July 2020
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 34 (11)
Cobalt(II)/(III) complexes bearing a tetradentate thiosemicarbazone: Synthesis, experimental and theoretical characterization, and electrochemical and antioxidant properties
New cobalt complexes, Co1 and Co2, were synthesized starting from acetylacetone‐S‐methylthiosemicarbazone. The square planar cobalt(II) and octahedral cobalt(III) complexes were characterized by FT‐IR, UV–visible, 1H NMR, and X‐ray diffraction spectroscopies and mass spectrometry. Frontier orbitals of the complexes were theoretically obtained to better understand the complex structures and intermolecular interactions. The electrochemical behaviors of Co1 and Co2 were investigated and the results were evaluated by comparing with each other and with similar published compounds to determine their possible usage in various electrochemical technologies, such as energy storage devices, electrocatalysts, and electrosensors. Metal‐based oxidation at around 0 V and metal‐based reduction at around −1.0 V indicated that these complexes are valuable for the proposed applications. By determining the trolox equivalent antioxidant capacity and the radical scavenging activity of the cobalt complexes, the compatibility between the antioxidant qualification, redox, and theoretical calculation results was discussed.
- 15 May 2020
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 44 (22) , 9313-9320
Structural characterization of new zinc(ii) complexes with N2O2 chelating thiosemicarbazidato ligands; investigation of the relationship between their DNA interaction and in vitro antiproliferative activity towards human cancer cells
New candidates to become DNA-targeting antiproliferative agents: Zinc(ii) complexes bearing N2O2-thiosemicarbazidato ligands.
- 15 May 2020
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 44 (22) , 9313-9320
Structural characterization of new zinc(ii) complexes with N2O2 chelating thiosemicarbazidato ligands; investigation of the relationship between their DNA interaction and in vitro antiproliferative activity towards human cancer cells
New candidates to become DNA-targeting antiproliferative agents: Zinc(ii) complexes bearing N2O2-thiosemicarbazidato ligands.